First Trust Capital Management’s Aspire Biopharma ASBP Stock Holding History

First Trust Capital Management’s Portfolio ASBP Stock Details ASBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-107	Closed	-$1.41M	–	111
2024 Q1	$1.41M	Hold	107	–	–	0.12%	95
2023 Q4	$1.4M	Hold	107	–	–	0.11%	111
2023 Q3	$1.39M	Buy	+107	New	+$1.38M	0.08%	114
2023 Q2	–	Sell	-1,048	Closed	-$13.2M	–	145
2023 Q1	$13.2M	Buy	1,048 +490	+88%	+$6.13M	0.57%	50
2022 Q4	$6.9M	Hold	558	–	–	0.37%	87
2022 Q3	$6.79M	Hold	558	–	–	0.32%	91
2022 Q2	$6.69M	Buy	+558	New	+$6.68M	0.47%	49

Other funds holding ASBP

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

First Trust Capital Management's ASBP Position: Q2 2024 in Review

First Trust Capital Management sold out of Aspire Biopharma (ASBP) in Q2 2024, closing a stake of 107 shares — an estimated $1.41M sold.

First Trust Capital Management first reported a position in ASBP in Q2 2022 and held it in 7 quarters. The position peaked at $13.2M in Q1 2023. 3 funds tracked by Wall St. Rank hold ASBP as of Q2 2024.

First Trust Capital Management reported no remaining Aspire Biopharma position as of Q2 2024 after selling out during the quarter.
First Trust Capital Management sold 107 Aspire Biopharma shares in Q2 2024, an estimated $1.41M.
First Trust Capital Management first reported a position in Aspire Biopharma in Q2 2022 and held it in 7 quarters.
First Trust Capital Management's Aspire Biopharma position peaked at $13.2M in Q1 2023.
3 funds tracked by Wall St. Rank held Aspire Biopharma as of Q2 2024.

Based on First Trust Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.